全文获取类型
收费全文 | 2709篇 |
免费 | 441篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 118篇 |
妇产科学 | 27篇 |
基础医学 | 211篇 |
口腔科学 | 36篇 |
临床医学 | 377篇 |
内科学 | 729篇 |
皮肤病学 | 125篇 |
神经病学 | 254篇 |
特种医学 | 311篇 |
外科学 | 343篇 |
综合类 | 51篇 |
预防医学 | 225篇 |
眼科学 | 32篇 |
药学 | 252篇 |
中国医学 | 1篇 |
肿瘤学 | 79篇 |
出版年
2023年 | 56篇 |
2022年 | 18篇 |
2021年 | 42篇 |
2020年 | 97篇 |
2019年 | 21篇 |
2018年 | 100篇 |
2017年 | 81篇 |
2016年 | 76篇 |
2015年 | 77篇 |
2014年 | 108篇 |
2013年 | 134篇 |
2012年 | 88篇 |
2011年 | 75篇 |
2010年 | 97篇 |
2009年 | 125篇 |
2008年 | 82篇 |
2007年 | 86篇 |
2006年 | 85篇 |
2005年 | 66篇 |
2004年 | 54篇 |
2003年 | 52篇 |
2002年 | 60篇 |
2001年 | 73篇 |
2000年 | 52篇 |
1999年 | 70篇 |
1998年 | 88篇 |
1997年 | 106篇 |
1996年 | 85篇 |
1995年 | 85篇 |
1994年 | 57篇 |
1993年 | 62篇 |
1992年 | 52篇 |
1991年 | 35篇 |
1990年 | 64篇 |
1989年 | 97篇 |
1988年 | 67篇 |
1987年 | 58篇 |
1986年 | 47篇 |
1985年 | 47篇 |
1984年 | 36篇 |
1983年 | 23篇 |
1982年 | 33篇 |
1981年 | 28篇 |
1980年 | 22篇 |
1979年 | 22篇 |
1978年 | 23篇 |
1977年 | 20篇 |
1976年 | 17篇 |
1973年 | 13篇 |
1971年 | 15篇 |
排序方式: 共有3189条查询结果,搜索用时 531 毫秒
1.
2.
3.
P. A. Milligan P. E. McGill C. W. Howden A. W. Kelman B. Whiting 《European journal of clinical pharmacology》1993,45(6):507-512
Summary A randomised crossover study was performed in subjects with rheumatoid arthritis (or other arthropathies) to investigate if any alteration in the steady pharmacokinetics of the NSAID piroxicam (a drug which is extensively metabolised via cytochrome P450) or its major metabolites occurred as a result of coadministering either cimetidine or nizatidine.Twelve females and 2 males with mean age, weight, and albumin concentrations of 58 years, 61 kg, and 40 g·L–1 respectively, completed the study. Comparisons were made between the following parameters: plasma piroxicam AUCs [AUC0-24(P)], plasma 5-hydroxypiroxicam AUCs [AUC0-24(5-OHP)], the ratio of these i.e. AUC0-24(5-OHP):AUC0-24(p), the % piroxicam daily dose excreted in urine as 5-hydroxypiroxicam (before and after glucuronidase incubation); and the mean of the steady state trough piroxicam, and 5-hydroxypiroxicam concentrations (obtained during each study phase in addition to the wash-out period).A statistically significant difference as a result of initiating either cimetidine or nizatidine was obtained only for the ratio AUC0-23(5-OHP):AUC0-24(P). This was indicative of a weak potential to inhibit piroxicam hydroxylation.No clinically significant alteration in the steady state pharmacokinetics of piroxicam occurred in these subjects as a result of cimetidine or nizatidine coadministration. Consequently it is unlikely that any adverse events would arise from these combinations. 相似文献
4.
5.
6.
7.
The pharmacokinetics of gamma-glutamyl-L-dopa in normal and anephric rats and rats with glycerol-induced acute renal failure. 总被引:2,自引:2,他引:0 下载免费PDF全文
Y. A. Boateng H. E. Barber T. M. MacDonald J. C. Petrie M. R. Lee P. H. Whiting 《British journal of pharmacology》1990,101(2):301-306
1. The pharmacokinetics of gamma-glutamyl-L-dopa (gludopa) and its metabolite, L-dopa, have been studied in normal rats at three dose levels of gludopa: 2 mg kg-1, 5 mg kg-1 and 7.5 mg kg-1. The extent of metabolism in normal rats, and the pharmacokinetics in anephric rats and rats with glycerol-induced acute renal failure (ARF) were also studied at a gludopa dose of 2 mg kg-1. 2. Gludopa was extensively metabolised to L-dopa with only about 10% of an injected dose being excreted unchanged. Normal rats had a rapid gludopa clearance of 50.9 +/- 9.6 ml min-1 kg-1 and elimination rate constant of 2.99 +/- 0.27 h-1. The mean residence time and half-life were 20.9 +/- 1.4 and 14.4 +/- 1.0 min, respectively. The apparent volume of distribution at steady state was 1.05 +/- 0.18 l kg-1. 3. No statistically significant differences were found in the main pharmacokinetic parameters between ARF and controls for either gludopa or its metabolite L-dopa. 4. In anephric rats and controls the kidneys were found to contribute about 68.5% and 67.2% to the elimination of gludopa and the metabolite L-dopa, respectively. 5. These results confirm that gludopa is an efficient pro-drug for L-dopa, and that the kidneys are the major site of gludopa metabolism. It seems likely that the renal specificity of gludopa persists in ARF. 相似文献
8.
9.
10.
筛检对肝癌死亡率影响的研究 总被引:5,自引:0,他引:5
5581名HBsAg阳性的男性随机分入周期性筛检组(A组,3712人)及对照组(B组,1869人)。A组(19155.4人年)共发生肝癌257例,B组(9785.5人年)为117例,两组的肝癌发生率分别为1342/10万与1196/10万;两组肝癌死亡分别为218与109例,肝癌死亡率分别为1138/10万与1114/10万。两组中Ⅰ期肝癌病例分别为29.6%与6.0%,差异有非常显著性意义。1、3、5年相对生存率A组为23.7%、7.0%、4.0%,B组为9.7%、4.0%、4.1%。用Poisson回归模型拟合显示,在调正年龄、初筛AFP及入列年份后,筛检对于肝癌的相对危险度为0.83,95%CI为0.68~1.03,有较弱的“保护”作用,Cox回归模型拟合结果显示当临床分期未引入模型时,筛检对于肝癌有显著的“保护”作用:危险率为0.6617,95%CI为0.5234~0.8365;而模型经调整后,危险率即接近“1”,95%CI为0.74~1.26。 相似文献